Skip to main content
Premium Trial:

Request an Annual Quote

Herbert Fritsche, James Mullen

Premium

Herbert Fritsche has joined the scientific advisory board of Health Discovery, of Waco Texas. Fritsche is currently a professor of laboratory medicine and chief of the clinical chemistry section at The University of Texas, M.D. Anderson Cancer Center in Houston, where he has been a researcher for 35 years. Health Discovery is a discovery company that uses computational modeling to identify diagnostic and therapeutic targets.


James Mullen has been elected to the board of directors of PerkinElmer. Mullen is CEO of Biogen Idec. He was formerly chairman of the board and CEO of Biogen. He has also served at Biogen as president; director of facilities and engineering; vice president of operations; and vice president international. Prior to joining Biogen, Mullen had various positions at SmithKline Beecham. He holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.